Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...
Hackensack University Medical Center, Hackensack, New Jersey, United States
University of California Los Angeles (UCLA), Santa Monica, California, United States
Princess Margaret, Toronto, Ontario, Canada
University of Florida, Gainesville, Florida, United States
Severance hospital, Seoul, Korea, Republic of
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
University of Minnesota, Minneapolis, Minnesota, United States
UCSF, San Francisco, California, United States
IU Health Methodist Hospital, Indianapolis, Indiana, United States
Children's Medical Center UTSW, Dallas, Texas, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States
16, Changchun City, China
1, Guangzhou, China
20, Guangzhou, China
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.